STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer (2016)
- Authors:
- Autor USP: SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1002/cjp2.55
- Subjects: NEOPLASIAS OVARIANAS; QUIMIOTERAPIA; IMUNIDADE
- Keywords: Interferon; Intratumoural CD8+ T cell; Ovarian cancer; Chemoresistance; STAT1
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2016
- Source:
- Título: The Journal of Pathology : Clinical Research
- ISSN: 2056-4538
- Volume/Número/Paginação/Ano: v. 2, n. 4, p. 259-270, 2016
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
AU, Katrina K. et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, v. 2, n. 4, p. 259-270, 2016Tradução . . Disponível em: https://doi.org/10.1002/cjp2.55. Acesso em: 01 abr. 2026. -
APA
Au, K. K., Page, C. L., Ren, R., Meunier, L., Clément, I., Tyrishkin, kathrin, et al. (2016). STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, 2( 4), 259-270. doi:10.1002/cjp2.55 -
NLM
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1002/cjp2.55 -
Vancouver
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2026 abr. 01 ] Available from: https://doi.org/10.1002/cjp2.55 - A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
- Extracellular vesicles: evolving factors in stem cell biology
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- In silico shows that PTEN loss and AR overexpression are associated with increased CD8+ T-cell and Treg density and earlier disease recurrence in prostate cancer
- In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in sity hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
- PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
- Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Application of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting PTEN loss in diagnostic prostate cancer needle biopsies
- Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
